Intellia Therapeutics (NTLA) Expected to Post Quarterly Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) is projected to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.80) per share and revenue of $12.98 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.11. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.The business had revenue of $15.05 million during the quarter, compared to analysts’ expectations of $13.81 million. During the same period last year, the firm earned ($1.10) EPS. On average, analysts expect Intellia Therapeutics to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Intellia Therapeutics Price Performance

Intellia Therapeutics stock opened at $10.80 on Thursday. The stock’s 50 day moving average price is $13.92 and its 200 day moving average price is $13.51. Intellia Therapeutics has a 1-year low of $7.95 and a 1-year high of $28.25. The company has a market cap of $1.51 billion, a PE ratio of -3.05 and a beta of 1.77.

Analyst Upgrades and Downgrades

Several brokerages have commented on NTLA. Leerink Partners set a $35.00 target price on shares of Intellia Therapeutics in a research report on Monday, April 27th. Sanford C. Bernstein increased their price target on shares of Intellia Therapeutics from $13.00 to $17.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Friday, July 17th. Citigroup reissued a “market outperform” rating on shares of Intellia Therapeutics in a report on Monday, June 15th. Finally, Citizens Jmp restated a “market outperform” rating and set a $30.00 target price on shares of Intellia Therapeutics in a research report on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, nine have issued a Hold rating and four have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $20.19.

Insider Buying and Selling at Intellia Therapeutics

In related news, EVP Edward J. Dulac III sold 4,677 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total value of $84,186.00. Following the sale, the executive vice president directly owned 156,286 shares in the company, valued at $2,813,148. The trade was a 2.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Michael P. Dube sold 2,641 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total transaction of $44,315.98. Following the completion of the sale, the chief accounting officer directly owned 66,886 shares in the company, valued at approximately $1,122,347.08. The trade was a 3.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Intellia Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NTLA. Virtu Financial LLC acquired a new stake in shares of Intellia Therapeutics in the fourth quarter valued at approximately $245,000. Invesco Ltd. raised its position in shares of Intellia Therapeutics by 5.8% during the 4th quarter. Invesco Ltd. now owns 433,290 shares of the company’s stock worth $3,895,000 after purchasing an additional 23,870 shares during the last quarter. Axxcess Wealth Management LLC lifted its stake in Intellia Therapeutics by 20.1% in the 4th quarter. Axxcess Wealth Management LLC now owns 21,399 shares of the company’s stock valued at $192,000 after buying an additional 3,583 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new stake in Intellia Therapeutics in the 4th quarter valued at approximately $90,000. Finally, XTX Topco Ltd acquired a new stake in Intellia Therapeutics during the 4th quarter valued at $402,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.